Oslo University Hospital begins ALS study with TikoMed’s drug candidate ILB[®]

PRESS RELEASE

Stockholm-Oslo 13 March, 2026

Oslo University Hospital has now begun the inclusion of patients in the IMPACT study, which aims to investigate the efficacy and safety of TikoMed’s candidate drug ILB® compared to riluzole for the treatment of ALS. TikoMed provides ILB® and placebo substance for the study.

The study will include 120 patients from all over Norway and includes a randomized phase of 6 months where patients receive either ILB® or riluzole followed by a 6-month open-label phase where patients receive both medications. Therefore, after the initial six-month period, all patients will receive ILB®.

‘We are very much looking forward to this groundbreaking study and we would like to strongly encourage all Norwegian ALS patients who qualify for the study to seek participation through their neurologist,’ says Björn Pilström, CEO and Chief Medical Officer of TikoMed.

About TikoMed AB

TikoMed is a Swedish biotechnology company focused on developing innovative treatments based on the ILB® platform. The company manufactures ILB® and conducts research in acute and chronic diseases with large unmet medical need. For more information visit www.tikomed.com.

About Oslo University Hospital

Oslo University Hospital is one of the leading university hospitals in the Nordic region and conducts advanced academic research in several fields, including neurological diseases. For more information about the study (only in Norwegian): https://www.oslo-universitetssykehus.no/om-oss/nyheter/als-studie-i-gang-ved-ous/.

Tags: